Internal-ion gated electrochemical transistors

    公开(公告)号:US12144191B2

    公开(公告)日:2024-11-12

    申请号:US17352622

    申请日:2021-06-21

    Abstract: An internal-ion gated electrochemical transistor is provided. In some embodiments, the internal-ion gated electrochemical transistor comprises: a gate electrode, a source electrode, and a drain electrode; a channel formed between the source electrode and the drain electrode, wherein the channel comprises a conducting polymer, wherein the channel serves as a reservoir of positively charged mobile ions; and an ion membrane between the channel and the gate electrode, wherein: in an off state, at least a subset of the positively charged mobile ions are ionically bonded to negatively charged ions of the conducting polymer, and wherein in an on state, at least a subset of the positively charged mobile ions are unbonded from the negatively charged ions of the conducting polymer to induce a current within the channel, and wherein at least one of the off state and the on state is actuated by application of a voltage to the gate electrode.

    Method of treating adenoid cystic carcinoma

    公开(公告)号:US12115140B2

    公开(公告)日:2024-10-15

    申请号:US17391853

    申请日:2021-08-02

    CPC classification number: A61K31/192 A61K31/203

    Abstract: The method of treating adenoid cystic carcinoma or other cancer tumors includes the administration of an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof, alone or in combination with other cancer treatment. Non-limiting examples of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid (commonly referred to as “BMS493”) and 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl] ethynyl]benzoic acid (commonly referred to as “AGN193109”). Alternatively, prior to administration of the inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling, a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling may be administered to the patient. Non-limiting examples of a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include all-trans retinoic acid (ATRA), isotretinoin, alitretinoin, and bexarotene.

Patent Agency Ranking